spectacular year diabet devic stock tough act follow
remain enthus see minim risk vs expect across group
long-term outlook remain compel multipl key catalyst see
greatest potenti upward estim revis top bottom line
remain top pick diabet devic link
three larger cap diabet devic stock outperform
significantli outperform
broader med-tech ihi revenu estim revis upward
three compani though multipl expans biggest driver share
appreci except revenu estim increas
vs vs stock gain greatest beneficiari multipl expans
gain share despit increas revenu
ntm p/ basi diabet devic stock continu trade histor averag
vs year averag vs averag
vs averag howev histor high profit rapidli
scale take longer move right direct
primari focu investor current robust eps/fcf growth outlook
becom greater appreci next year well help provid rel
downsid protect investor level like expect
competitor healthcar confer januari expect provid
result guidanc januari et dont expect
guidanc late februari
new product launch dxcm tndm control-iq podd horizon within
coverag mdt abt libr outsid coverag jen lay
foundat new market clinic trial data/partn progress non-intens
type patient signific number catalyst come page
detail catalyst expect relev dxcm/podd/tndm
page brief summari expect near medium term new product
pleas see page report import disclosur
setup share result attract upsid
case could temper manufactur constraint still expect least
beat vs high end guidanc given posit intraquart commentari
manufactur bottom-up basi ignor manufactur constraint could see
room revenu upsid ep upsid still see room
signific revenu ep upsid vs consensu
expect regardless libr time
continu view core long term hold best product pipelin
sensor softwar vast under-penetrated market opportun
expect share grind higher next month driven continu execut vs
expect launch grow investor confid long
term non-intens type adopt clinic trial data key partner progress
expect increas price target base dcf
analysi repres sale p/fcf
overal expect rel benign quarter result releas
februari expect exceed consensu revenu expect
wouldnt expect anoth signific beat like although
said thing ahead also dont expect materi upsid vs current
consensu revenu expect although there clear potenti path upsid
outlin page
importantli compel long term outlook remain intact anoth
gain unlik stock wed recommend own
clear path revenu growth forese futur nearli
recur revenu attract gross margin current manag
target room beyond rapidli scale
profit differenti competit posit tubeless option
autom insert pharmaci channel strong manag team see
neg catalyst next month horizon launch repres
clear excit catalyst share neg point stock
valuat share trade sale sale
premium vs howev dcf analysi continu suggest bia
upsid rais price target upsid dcf analysi
suggest share could approach time continu like long term
outlook wed buyer weak throughout
think setup share result releas late februari neutral
slightli posit aid recent declin investor sentiment/expect
reduc forecast midpoint manag guidanc
consensu effort conserv later expect control-iq launch
call poor result expect result fine see path
potenti better expect revenu via less control-iq purchas decis paus
expect and/or ou upsid
believ share alreadi price rel less compel
setup attract product pipelin control-iq sport/phon control
next gen algorithm expect continu take notabl market share
next year expect clear upsid vs estim driven
control-iq launch manag also made impress gain gross margin
past year improv long term profit outlook accordingli see
howev still sentiment driven stock limit profit expect
next year clear risk investor sentiment enter
multipl current competitor launch new product
addit competit approach ensu month beta bionic potenti
still believ fundament outlook attract recent declin share
improv risk/reward stock trade sale
sale discount vs dxcm/podd howev even competit new
product launch dont harm financi overhang sentiment seem like
persist least late absent materi revenu and/or margin upsid
accordingli reduc price target repres sale
thomson eikon cowen compani
thomson eikon cowen compani
cowen compani
note estim adjust estim verili payment
thomson eikon cowen compani
note estim rais late decemb link
thomson eikon cowen compani
thomson eikon cowen compani
januari competitor healthcar confer present monday januari
et expect provid result guidanc like prior
present
libr launch limit visibl though like point next
unitedhealthcare/oth partner updat non-intens type program
limit visibl though expect year notabl progress
readout commit studi link studi intermitt cgm use amongst type
patient oral medic baselin trial end may
data ada
financi updat competitor healthcar confer month
horizon pivot trial conclusion/data trial expect complet may
horizon launch expect
tidepool loop launch potenti expedit via new interoper
autom glycem control class loop algorithm may
file late earliest observ studi expect
loop partner may provid
particularli import benefit like fastest rout
iphon control autom insulin deliveri horizon
approv first specif android model
launch like togeth
meaning product launch howev cant hurt alreadi strong type
financi updat competitor healthcar confer month
control-iq launch end januari
sport fda file summer like launch around earli
unitedhealthcar coverag agreement limit visibl like point
like captur estim
outperform price
expect provid preliminari result competitor confer
januari forecast revenu consensu high end
manag guidanc manufactur constraint could temper upsid case
process ad signific capac eas constraint
earli latest guidanc assum manufactur constraint revenu
although intraquart commentari suggest capac like better
could envis addit upsid vs forecast
consensu ep consensu manufactur constraint
could temper upsid still expect solid result least modest
bottom-up basi ignor potenti manufactur constraint
notabl sourc upsid vs alreadi consensu revenu forecast sensor
util revenu estim assum averag sensor util
y/i q/q acknowledg strong quarter
past year util increas q/q assum util
instead roughli flat y/i q/q would result upsid
vs above-consensu revenu forecast assum upsid new
current model revenu ep consensu
expect respect believ bia upsid ultim expect
exceed consensu revenu ep expect
respect said expect initi revenu growth guidanc
repres greater growth line current consensu
expect provid competitor confer earli januari
averag annual revenu per patient declin y/i impli price
headwind averag sensor util per patient vs
seemingli modest increas y/i see limit downsid risk
assumpt potenti upsid across three key metric
rel model follow assumpt would result
revenu upsid y/i revenu growth overal new patient add grow
y/i equat increment us intens manag penetr
vs current forecast would still impli notabl deceler us market
growth declin total us cgm new patient add y/i averag annual
revenu per patient declin impli price headwind
estim sensor util roughli flat y/i
upsid assumpt appear reason us importantli dont
believ would meaning impact libr anyth outlook new
patient addit upsid could aid libr launch particularli given abt
commentari regard significantli increas advertis clear posit
increas awareness/fingerstick convers via libr clear
tailwind past year
continu view core long-term hold best product pipelin
sensor softwar vast under-penetrated market opportun
believ investor focu competit price dynam particular
overdon expect share grind higher next month driven
continu execut vs expect launch grow
investor confid long term non-intens type adopt increas
price target base dcf analysi repres sale
line current sale multipl p/fcf abl post
result closer upsid case share could ultim approach
next month
outperform price
overal expect rel benign quarter result releas
februari expect exceed consensu revenu expect
dont expect anoth signific beat like although said
thing ahead
modestli increas revenu forecast though remain line
consensu see path upsid vs forecast high end
guidanc driven us ou diabet busi within us
catalyst drive acceler growth remain intact pharmaci dash do-it-yourself
loop type ou busi guidanc appear conserv season
trend busi assum flat q/q even account modest fx
headwind expect least slight beat recent ou dash launch cant hurt
increas revenu forecast model revenu line
consensu continu like setup share enter clear
neg catalyst tndm sport launch closest neg catalyst
envis horizon launch like acceler new patient addit
gain market share today despit vendor without
cgm-autom featur horizon launch add autom insulin deliveri
well enabl phone control effect elimin devic patient repres
huge potenti catalyst stock
dont current expect meaning upsid vs consensu revenu expect
envis path occur via multipl avenu compani
result survey data suggest us insulin pump market acceler
us new patient start come mdi among best posit
benefit acceler could us new patient upsid vs forecast
via better expect market growth forecast share gain
forecast us market share gain possibl
transit us instal base pharmaci
current anticip drive upsid price assumpt
scale launch dash intern expect begin expand
new ou geographi beyond start smaller eu countri
current presenc and/or middl east could clear driver upsid vs
current forecast ou revenu growth could
neg point stock valuat trade
sale sale premium vs howev dcf
analysi continu suggest bia upsid anoth gain
unlik stock wed recommend own clear path
revenu growth forese futur nearli recur revenu
attract gross margin current manag target
room beyond rapidli scale profit
differenti competit posit tubeless option autom insert
pharmaci channel strong manag team see neg catalyst
next month horizon launch repres clear excit
upcom catalyst share rais price target
upsid dcf analysi suggest share could approach time continu
like long-term outlook wed buyer weak throughout
outperform price
think setup share result releas late februari neutral
slightli posit aid recent declin investor sentiment/expect
reduc revenu forecast model revenu
consensu line midpoint manag guidanc reduct
attempt conserv later expect control-iq approv ultim
expect least achiev forecast achieve/exce consensu
revis revenu forecast assum us new patient addit increas
q/q first blush doesnt scream conserv particularli given
manag commentari regard patient paus purchas new pump
launch control-iq expect end januari howev weve heard
corrobor physician weve also heard multipl physician
purchas decis paus consist incent
patient pocket cost significantli lower purchas vs
deduct reset purchas enabl quickest rout control-iq
adopt avail via free remot softwar upgrad also worth note
model revenu high end fy guidanc forecast
assum q/q declin new patient addit present clear potenti
sourc upsid launch basal-iq/geograph expans off-set
reduc pool anima patient convert
call poor result expect result fine see path
potenti better-than-expect revenu via less purchas decis paus
dont see ton room revenu upsid though expect achiev
consensu revenu expect see path modest upsid share
flat past month investor continu digest multipl
factor make setup rel less compel recent histori
appear less room revenu upsid investor grown
accustom past year although expect clear upsid vs
expect driven control-iq potenti ou upsid anima convers
signific driver new patient shipment total new patient
shipment us new shipment declin materi vast
major patient alreadi chosen new pump multipl new competit
system expect launch contrari
compani launch meaning new product primari
howev believ much concern alreadi bake investor
expect speak expect materi revenu upsid
still believ consensu estim reasonable/achiev primari
driver confid launch control-iq us
quarter head start launch new product launches/geograph
expans ou well potenti coverag agreement
within us forecast assum y/i new patient growth gain
us market share exit assum garner similar
share mdi convers estim estim exclud
anima need attract addit competit convers
us new product
horizon present risk sourc patient howev
also clear tailwind control-iq among anticip new product
launch pump market histori market quarter prior
launch also expect control-iq compet effect upon
launch dxcm critic differenti eas use
patient renew pool patient target
per ada present coverag agreement unitedhealthcar
recal remov coverag adult patient follow restrict
children earli link visibl limit strong clinic data
control-iq publish new england journal medicin logic reason
cover product point besid lower price receiv
coverag agreement could easili add revenu
expect depend time like account us type
outsid us see limit risk forecast believ bia clearli
upsid current forecast y/i declin ou new patient add
entir driven declin anima convers howev multipl
catalyst could drive upsid forecast includ new product launch across
tndm ou busi basal-iq potenti control-iq mani market via
softwar updat geograph expans multipl major market germani
franc etc could envis ou revenu grow vs current growth
forecast either drive upsid offset margin us weak everi
increment ou revenu growth equival us new patient growth
low believ share alreadi price rel less
compel setup amongst best product pipelin pump
industri control-iq sport/phon control next gen algorithm expect
continu take notabl market share next year
manag also made impress gain gross margin past year
improv long-term profit outlook accordingli see limit downsid risk
howev still sentiment-driven stock limit profit expect
next year clear risk investor sentiment enter
multipl current competitor launch new product
addit competit approach ensu month beta bionic potenti
still believ fundament outlook attract recent declin share
improv risk-reward stock trade sale
sale discount vs dxcm/podd howev even competit new
product launch dont harm financi overhang sentiment seem like
persist least late absent materi revenu and/or margin upsid
accordingli reduc price target repres sale
compani report thomson eikon cowen compani
quarterli snapshot result guidanc januari pt et cowen vs consensu mm except non-gaap revenu metric mm except statement mm except per count maintain durabl revenu forecast flat y/i forecast assum new patient add y/i q/q basi conserv given robust new patient growth past year seem reason given typic seasonality/manag commentari beyond new patient forecast assum acceler declin receiv sale deceler transmitt revenu growth includ roughli flat q/q util appear quit conserv maintain sensor revenu forecast repres growth y/i bottom basi ignor manufactur constraint could envis beat sensor util upsid alon manag guidanc account product constraint although worth note commentari investor confer suggest bia upsid guidanc expect least modest beat maintain ep forecast consensu bia upsid though import revenu perform maintain revenu forecast y/i high end manag guidanc bottom basi see room least revenu beat driven sensor util howev guidanc account manufactur constraint potenti hamper upsid quarter intraquart commentari investor confer suggest product capac could bit better assum within guidanc accordingli expect least modest beat maintain gross margin forecast consensu though line full year guidanc maintain forecast maintain sg forecast maintain oper margin forecast consensu revenu upsid margin upsid would like even greater cowen
compani report thomson eikon cowen compani
quarterli snapshot insuletconfer call februari et dial-in passcod vs consensu mm except flat y/i due scale new facil re-affirmed oper high end msd oper margin rang revenu metric mm except statement mm except market earn per count larg maintain ou omnipod forecast reduc due fx believ bia upsid forecast driven seemingli conserv fx guidanc like conserv underli busi assumpt across new patient add exist patient util flat slightli q/q expect least reach exceed forecast recent dash launch hurt increas ep forecast remain consensu though expect ultim reach modestli exceed expect maintain drug deliveri revenu forecast low end guidanc onpro continu maintain high market share overal neulasta dose biosimilar gain share expect busi forese futur absent new collabor launch increas revenu forecast believ bia remain upsid forecast driven core diabet busi expect ultim exceed us ou omnipod forecast howev believ prudent expect modest beat vs past two blow-out beat quarter bottom basi estim appear particularli conserv hope surpris upsid increas gross margin forecast though remain consensu forecast also manag guidanc prefer remain conserv continu face headwind ramp new us facil regardless long term gross margin trajectori remain intact excit maintain forecast maintain forecast maintain forecast increas oper profit forecast margin driven increas revenu gross margin increas us omnipod revenu forecast forecast near albeit slightli high end manag guidanc rang ultim reason recent robust momentum slow catalyst drive acceler new patient add pharmaci dash do-it-yourself loop type remain intact base recent preced seem like exceed forecast said bottom basi none assumpt appear particularli conserv q/q new patient start growth pod per patient per month util consist surpris year cowen
compani report thomson eikon cowen compani
quarterli snapshot tandemcowen vs consensu mm except impli re-affirmed oper adj ebitda margin revenu metric mm except growth statement mm except earn per y/i nmnmnmshare count reduc revenu forecast y/i driven reduct new patient forecast entir within us forecast assum us new patient add q/q scream conserv believ abl least reach forecast despit later expect approv control-iq launch januari worth note possibl control-iq approv headlin spur strong end us forecast assum signific q/q declin ou new patient add due materi anima drop could sourc upsid reduc suppli revenu forecast y/i see potenti modest upsid driven strong season demand unlik materi move needl vs consensu expect reduc revenu forecast y/i forecast consensu directli line midpoint manag guidanc ultim still expect reach expect howev given later expect approv control-iq seemingli reduc buysid expect decid conserv could envis upsid vs high end guidanc driven patient purchas pump prior deduct re-set know control-iq avail via free upgrad better expect intern result call poor result think result fine increas oper loss forecast due revenu gross margin reduct expect least adjust ebitda margin ex stock comp maintain sg forecast maintain forecast reduc gross margin forecast due lower pump revenu mix forecast consensu cowen
compani report cowen compani
companyproductcommerci timelinesdistinguish enhanc launchedimprov data limit launch broad roll-out tbd decis support systemsmedtronicnon-adjunct guardian stand-alone us april fda submiss impli fda submiss like late earli reduct fingerstick vs guardian expect meet icgm criteria synergyu fda submiss impli late earli submiss like mid late launch fulli dispos volum reduct new step insert still expect requir day calibr sensor guardian improv algorithm/form factor per management convo ada address open item fda approv point launch octob termtbasenseonicseversens dayu clinic trial expect run like late launch ou launch dayus/ tbdextend wear day us/ou tbdagamatrix waveform cascadeu expect launchou expect late launchlifescan/nova biomedicaltbdu tbdou earli cgmu tbdou launch tbdou select market launch submit fda seemingli launch ou launch august icgm systemus/ tbdimplant sensor extern receiv year sensor life like requir calibr bit bulki privat monitormetronom biolinq sano other continu glucos monitor cgm product pipelin tracker dispos miniatur lower cost mayb day wear like perform improv reduc calibr one day unclear mani thereaft insulin dose claim like enabl reimburs geograph specif commentari like launch along insulin pen partner lilli novo etc start term flash capabl batteri incorpor sensor remov transmitt addit analytesnon-invas cgm patch skin electr current draw glucos skin report strong accuraci metric although data appear like replic real world skeptic given challeng non-invas monitor compani data present intern work aid typezero acquisit action treatment recommend mdi user core featur current libr factori calibr day wear trend data plu option alerts/alarm still requir interrog sensor glucos data like materi perform improv base icgm commentari data present ada made clear much pipelin includ addit analyt beyond glucos solid accuracy/reli per clinic trial data physician check product still requir calibr non-adjunct claim like inferior accuraci requir calibr seemingli shorter wear time limit detail date technolog acquir isens earli clearli current market leader despit inclus calibr data shown accuraci peer eas use inferior leader requir calibr long term market viabil unclear pend improv cowen
compani report cowen compani
productcommerci timelinesdistinguish launchou tbd person close loop us fda submiss impli late earli submiss like mid late launch ou tbdinsulethorizonu launchou tbdloopu observ studi on-going time suggest late launch possibl ou expect launch tandemcontrol-iqu launch end januari like launcht sportu summer fda submiss late launch ou tbdtidepoolloopu observ studi conclud bionicsilet insulin onlyu earli launch pivot expect initi tbdilet dual hormoneu launch like year post insulin launch ou tbdbigfoot biomedicalloopu launch first aid launch hardwar asant abbott cgm bigfoot autom insulin deliveri algorithm limit clinic data date also plan consolid prescript except insulin eli lillyhybrid close loop commerci name yet disclos us/ou potenti launch insulin pen launch launch screen durabl pump pre-fil insulin cartridg close loop develop timelin tbd us expect launch cgm collabor announc like ou alreadi launch us tbd studi support fda submiss forthcom othersroch eoflow sfc fluidic inreda cambridgetbddisk shape pump design deka cgm clinic data share date hybrid close loop run android control current use kaleido pump though explor option cgm insulin pump product pipelin tir target includ correct bolus waterproof expect time close loop close loop smartphon control initi select android devic earli time rang data amongst broad subset patient includ young pede encourag somewhat near commerci dual-hormon system develop util glucagon zealand theoret reduc sever hypoglycemia risk recent establish iagc class fda potenti creat faster path market current offici partner app resid patient smartphon miniatur pump screen phone control bolu button devic integr cgm control-iq algorithm insulin version util either cgm clinic data date solid tir focus simplic throughout user oper requir patient weight start small medium larg meal input predict algorithm modul suspend basal insulin deliveri cgm also autom correct bolus clinic data tir minim time hypo perhap importantli patient feedback data tir smartphon control meal predict although limit detail safeti protocol loop algorithm do-it-yourself commun taken fda tidepool compat icgm ace pump like fastest path iphon control autom insulin deliveri cowen
compani report thomson eikon cowen compani
mm except per share day profit day gener oper non-gaap day day less long termnet earn per consensu estim mm except per share gross op cowen
compani report thomson eikon cowen compani
mm except profit flat y/i due scale new facil re-affirmed target previous oper y/i re-affirmed high end msd oper margin rang target mid-teensincrement non-oper expens interest major interest expens non-cashearn per except per share gross op consensu estim cowen
compani report thomson eikon cowen compani
mm except cagrcommentstot impli profit re-affirmed oper adj ebitda margin non-cash stock aincrement interest earn per cowen vs consensu cowen
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
medic suppli devic diabet
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
medic suppli devic diabet
risk diabet devic sector may includ regulatori process potenti delay
commerci launch new product potenti price pressur payor/cm
premium rel valuat competit high level invest need compet
make invest recommend earli stage diabet devic compani base
upon assess technolog probabl market success competit
regulatori reimburs etc potenti market opportun event
success howev compani lack tradit and/or matur financi
metric believ specif methodolog assign price target
